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Abstract.
Background: Possession of APOE 4 is a strong risk factor for late-onset Alzheimer’s disease and is associated with loss of
synaptic proteins in the elderly even in the absence of Alzheimer’s disease.
Objective: We hypothesized that 4 allele possession in non-demented adults aged under-75 would also be associated with
alterations in the levels of synaptic proteins.
Methods: We measured synaptophysin, PSD95, drebrin, SNAP-25, and septin 7 by ELISA in hippocampus and superior
temporal gyrus from 103 adults aged <75 without dementia. Corresponding gene expression was measured by RT-PCR.
Results:There was no evidence that 4 affected levels of the proteins measured. Instead we found an increase in post-synaptic
proteins in the hippocampi of those with an 32 genotype. The evidence was strongest for drebrin (p = 0.011). There was
some evidence of increased synaptic protein gene expression in 4 carriers.
Conclusions: People with an APOE 32 genotype have a reduced risk of Alzheimer’s disease. It may be relevant that they
have a higher level of post-synaptic proteins in the hippocampus even in earlier adulthood.
Keywords: Alzheimer’s disease, APOE, dementia, drebrin, genetics, postmortem tissue, PSD-95, synaptic proteins, synap-
tophysin
INTRODUCTION
Alzheimer’s disease (AD) is a devastating neurode-
generative illness which affects the lives not only of
sufferers but also their caregivers. There is currently
no cure. It is the sixth most common cause of death in
the US and on average patients live for 4–8 years after
diagnosis [1]. In addition to the classical plaques and
neurofibrillary tangles, there is evidence of synaptic
degeneration from an early stage of disease [2]. It is
thought by some that synaptic loss is the hallmark of
early AD [2].
Although age is the strongest risk factor for devel-
oping sporadic AD, other risk factors have been
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identified. The strongest genetic risk factor for spo-
radic AD is possession of the 4 variant of the APOE
gene [3]. Possession of one copy of the 4 variant
increases the risk of AD three-fold and two copies
increase the risk up to ten-fold [4]. The 4 allele
also decreases the age at which dementia develops
but despite this many 4 carriers do not develop
dementia [5, 6]. Conversely the 2 variant reduces
the risk of AD, possibly by up to two-thirds [7–9].
Individuals with this variant have less AD neu-
ropathology before extreme old age [10, 11]. There
is evidence, predominantly from studies of middle-
aged and older adults, that this variant is associated
with better episodic memory performance [12]. In
postmortem brain studies and in PET studies of older
adults, 4 allele possession was associated with a
higher amyloid plaque load [13, 14]. In one study this
effect was seen even in middle-aged individuals [15].
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4 effects on neurofibrillary tangles are much less
consistent [16].
The effects of APOE genotype in earlier adult life
on the synapse are not clear. We investigated the
relationship between APOE genotype and markers
of synaptic degeneration by studying expression lev-
els of synaptic proteins. It was not possible (at the
point at which this project was planned) to study
all existing synaptic proteins so we chose proteins
which had been found to be affected in AD, influ-
enced by APOE genotype in older adults or would
provide information on an important synaptic pro-
cess. For example, synaptophysin is a 313 amino
acid, 38 kDa pre-synaptic vesicle-specific protein
[17, 18], which can be used as a marker of synap-
tic content. Most studies have found a reduction in
synaptophysin in AD [19–21]. Animal studies sug-
gested that the reduction begins very early in the
disease process but this finding was not replicated in
human postmortem studies [22–26]. There is some
evidence that 4 carriers with AD have a greater
reduction in synaptophysin than do non-4 carriers
[19, 21].
PSD-95 is a 724 amino acid protein, which is
associated with the post-synaptic membrane [17].
It is a member of the membrane-associated guany-
late cyclase family [27]. Conflicting findings have
been published on the changes in PSD-95 in AD.
One possible explanation is that as the pre-synaptic
input diminishes the size of the post-synaptic den-
sity increases initially to compensate, but the process
fails with continuing neurodegeneration and PSD-95
eventually decreases. This is, however, merely one
possible hypothesis to explain the observed findings.
Synaptosomal associated protein (SNAP-25) is a 206
amino acid protein which is part of the SNARE com-
plex involved in synaptic vesicle membrane docking
and fusion [28]. SNAP-25 was shown to be signifi-
cantly decreased in AD in some but not all studies [17,
20, 29–32]. One small study suggested that SNAP-25
is increased in 4 carriers [33].
Drebrin, which is involved in dendritic spine mor-
phogenesis, was shown to be reduced in dementia
but relatively few studies have been performed on
this protein [17, 22, 34]. Septin 7 is required for
the cell cytoskeleton to be organized normally and is
also involved in mitosis [17]. Although almost ubiq-
uitous, it is expressed at particularly high levels in
the CNS [35]. It is involved in dendritic spine for-
mation, a dynamic process affected by learning [36].
Downregulation of septin 7 has been shown to reduce
the complexity of the dendritic arbor [37]. Septin 7
has not been studied in AD or in relation to APOE
genotype.
Previous work in our laboratory demonstrated
reduced synaptic protein levels in older adults with-
out dementia who possessed an 4 allele [19]. To
our knowledge, there is no published information
on the effects of 4 on synaptic proteins in younger
adults. We hypothesized that synaptic proteins would
be lower in non-demented adults aged 18–75 with
than without an 4 allele. The neuronal synapse is
extraordinarily complex. As it was not possible to
study all of the proteins present at the synapse, we
made a pragmatic choice to focus on a small num-
ber proteins which had been found to be affected in
AD, influenced by APOE genotype in older adults,
or would provide information on a particular synaptic
process. We measured synaptic protein concentration
and gene expression in the hippocampus and superior
temporal gyrus.
METHODS
Study cohort
Samples were obtained from the Edinburgh Sud-
den Death Brain and Tissue Bank (SDBTB), the
South West Dementia Brain Bank (SWDBB), the
Parkinson’s Disease Brain Bank, the Thomas Willis
Oxford Brain Collection, and the London Neurode-
generative Diseases Brain Bank. All samples were
provided for this study in compliance with the terms
of Research Ethics Committee approval of the indi-
vidual brain banks. A minimum age of 18 and a
maximum of 75 were used for case selection. Cases
with up to Braak tangle stage III pathology were
included, as were those with small vessel disease
and micro-infarcts some distance from the regions
under investigation. Information was obtained on the
presence of all of these neuropathological findings to
allow later subgroup analysis. Clinical information
available on the individuals under investigation was
limited to the cause of their demise and any post-
mortem reports that were provided by the individual
brain banks.
In total, samples were obtained from 103 brains;
samples from both brain areas under investigation
were available for 92 of these. Samples were available
for RNA extraction in 190 of the 195 cases. Informa-
tion on donor age, cause of death, neuropathological
findings, and postmortem interval was available for
all brains used in this study. The mean age at death
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was 56.3 y; 29 people had been less than 50 y at the
time of death. Unfortunately for some individuals,
the postmortem delay was longer than 72 h. Because
of this, we explicitly examined between group differ-
ences in postmortem delay and included postmortem
delay in the linear regressions as a co-variate.
Cohort selection for immunohistochemistry
From the original cohort, 15 32 (all of those avail-
able with this genotype), 15 33, and 15 34 cases
were selected for immunohistochemistry on the hip-
pocampus. The 33 and 34 groups were matched
to the 32 group on age at death, gender, and post-
mortem delay as closely as possible. Unfortunately,
paraffin-embedded hippocampal tissue was not avail-
able for all of the cases. As a result, the 34 group
numbered only 13 and the 32 and 33 groups each
numbered 14.
Tissue preparation
Previously-dissected frozen tissue samples from
left hippocampus and superior temporal gyrus were
provided by all tissue banks other than the SWDBB.
Within the SWDBB, samples were dissected from
slices of left cerebral hemisphere that had been frozen
at –80◦C at the time of initial receipt of the brains.
All of the brain banks had similar procedures for
sampling, fixation (usually ∼3 weeks in buffered for-
malin) and detailed paraffin histology on blocks of the
right cerebral hemisphere, in keeping with protocols
agreed by the MRC UK Brain Bank Network.
For each frozen tissue sample, 200 mg were
homogenized in 1 ml chilled 1% SDS lysis buffer in
a Precellys homogenizer (2 × 15 s at 6000 × g) with
6 to 10 2.3-mm zirconia beads in a 2-ml screw cap
homogenate tube. The homogenates were centrifuged
at 13000 × g for 15 min at 4◦C. The supernatants
were kept on ice and aliquoted into 25l aliquots and
stored at –80◦C until required again. Paraffin sections
of hippocampus were cut at 7m thickness.
Measurement of SNAP-25 by indirect ELISA
Samples were diluted in coating buffer (0.01 M
sodium carbonate, 0.03 M sodium bicarbonate, pH
9.6) and 50l loaded per well. The recombinant pro-
tein standard (Abcam ab74529) was diluted in coating
buffer, with seven 3-fold serial dilutions forming
the standard curve (range = 0.003 ng/ l to 2 ng/ l).
Fifty l of standard was loaded per well. Blanks
consisted of 50l of coating buffer. The plate was
incubated at 26◦C for 2 h. The plate was washed 5
times in 0.05% PBS/Tween 20 (PBST), tapped dry
and non-specific protein binding blocked by incuba-
tion with 1% BSA/PBS at 26◦C for 1 h with agitation.
After a further 5 washes in PBST, the plate was tapped
dry and the detection antibody (Santa-Cruz Biotech-
nology SC376713) diluted 1:3000 in 1% BSA/PBS
was added for 2 h at 26◦C with agitation. Follow-
ing a further 5 washes with PBST, the plate was
tapped dry, and horseradish peroxidase-labelled sec-
ondary antibody (Vector labs, Burlington California,
USA) diluted 1:500 in PBS added for 30 min at 26◦C
in the dark with agitation. After a final 5 washes
with PBST, the plate was tapped dry, peroxidase sub-
strate added (R&D systems, 100l per well), and
the plate allowed to develop for 10 min. At the end
of this time, 50l of STOP solution was added to
each well. Absorbance at 450 nm was read in a multi-
detection microplate reader. In all ELISAs, absolute
protein levels were determined by interpolation from
the standard curve, and assays of all samples were
repeated at least once in addition to being performed
in duplicate on each plate.
Sandwich ELISA for drebrin, NSE, and
synaptophysin
As previously described in detail [38], drebrin,
NSE, and synaptophysin were measured by sandwich
ELISAs and PSD-95 was measured by an indirect
ELISA, which were designed in-house. Please refer
to Table 1 for details of the antibodies used in these
Table 1
Antibodies used in ELISAs
Target Provider Antibody code Dilution Use
Synaptophysin Abcam ab 53166 1:1000 Capture antibody
Synaptophysin Santa Cruz biotech sc-17750 1:1000 Detection antibody
Drebrin Abcam ab 11068 1:3000 Capture antibody
Drebrin Abcam ab60932 1:3000 Detection antibody
Septin 7 Abcam ab175229 1:500 Detection antibody
SNAP-25 Santa Cruz biotech sc376713 1:3000 Detection antibody
PSD-95 Sigma P246 1:3000 Detection antibody
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ELISAs. All assays used were developed using west-
ern blots to validate antibody specificity and serial
recombinant protein dilutions to assess sensitivity.
Measurement of Septin-7 by direct ELISA
Seven serial threefold dilutions of the recom-
binant protein (Cusabio, Wuhan China, CSB-
EP620952HU), and samples, all diluted 1:40 in 1x
coating buffer, were loaded in duplicate in clear 96-
well microplates prior to incubation at 4◦C overnight.
The range of the standard was 0.025 to 18.18 ng/ l.
The rabbit monoclonal antibody (Abcam ab175229)
used for detection was biotinylated with Lightning
Link modifier kit (Innova Biosciences, Cambridge
UK), incubated overnight at 4◦C and then quenched
prior to use. It could then be stored at 4◦C for up to a
week until required.
After overnight incubation, the plate was washed
with PBST, tapped dry, and non-specific protein bind-
ing was blocked by incubation with 5% milk/PBS at
room temperature for 90 min at 26◦C with agitation.
After further washes in PBST, the plate was tapped
dry. The biotinylated detection antibody, diluted
1:500 in 1%BSA/PBS, was added at room temper-
ature for 2 h at 26◦C with agitation. Bound antibody
was measured as above.
Postmortem protein stability
NSE mRNA and protein levels were previously
shown not to be affected by postmortem delay for at
least 72 h [39]. Synaptophysin, SNAP-25, and drebrin
protein concentrations were also previously shown to
be stable for up to 72 h postmortem [19, 38, 40, 41].
PSD-95 was previously shown to decrease slightly
after 72 h at room temperature but not when stored at
4◦C [38].
Postmortem stability of septin-7 has not previously
been assessed. Postmortem delay was simulated by
dissecting a piece of tissue from the anterior frontal
cortex of two cases with AD and two control brains,
all with a short postmortem delay (cases 4 and 5 h,
controls 5.5 and 6 h). The tissue was subdivided into
10 small pieces of equal weight. One piece was frozen
immediately at –80◦C. The others were stored at 4◦C
for 24, 48, or 72 h, or at room temperature for 6, 12,
18, 24, 48, or 72 h. At the end of the simulated post-
mortem delay all of the samples were homogenized in
SDS lysis buffer and frozen at –80◦C until required.
As shown in Supplementary Figure 2, septin 7 was
stable for up to 72 h under simulated postmortem
conditions.
Measurement of mRNA
As described previously, mRNA was extracted
from frozen brain tissue [40] and RNA concentration
determined by ribogreen quantification (Invitrogen
kit) before conversion to cDNA using a high-capacity
reverse transcription kit (Applied Biosystems, Fos-
ter City California, USA) [39]. Real-time PCR was
carried out using a Viia7 real-time PCR system. Taq-
man gene expression assays (Applied Biosystems)
which crossed exons were used for MAP2 (Hs0025
8900 m1), NSE (Hs00157360 m1), GAPDH (Hs027
58991 g1), SEPT7 (Hs00987502 g1), SYP (Hs0030
0531 m1), PSD-95 (Hs00176354), DBN1 (Hs00365
623 m1), and SNAP-25 (Hs00938962 m1). Gene
expression samples were incubated with Taqman
advanced fast mastermix and 10 ng of cDNA (total
volume of 20l) at 50◦C for 2 min, 95◦C for 20 s
and 40 cycles of 95◦C for 1 s, then 60◦C for 20 s.
Samples were analyzed in triplicate.
Choice of reference genes
It is usual when performing gene expression stud-
ies to determine the expression of the gene of interest
relative to that of a calibrator or reference gene, often
a so-called housekeeping gene and sometimes a gene
that is chosen because it has the same restricted cell-
type specific pattern of expression as the gene of
interest. This can help to reduce other sources of
variation, for example in overall RNA quantity or
(to some extent) quality, or in the relative number
of different cell types. GAPDH is a commonly used
reference gene as it is ubiquitously expressed at high
levels. It is less suitable for studies such as this one
precisely because it is ubiquitously expressed, as dis-
cussed in detail in Palmer et al. [42]. In keeping with
standard practice in our laboratory, for calibration we
therefore also used neuron-specific reference genes,
the expression of which within neurons is not directly
affected by AD: microtubule associated protein 2
(MAP2) and neuron specific enolase (ENO2) [40].
APOE genotyping
All ELISAs and RT-PCR assays were carried out
blind to APOE genotype. Initial genotyping of all
study participants for APOE was undertaken by inte-
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grated single-label liquid phase assay. Full details of
this method were published previously [43].
When the initial genotyping was performed there
appeared to be an excess of 4 alleles (specifically,
a large number of 44 genotypes) and the genotypes
were not in Hardy-Weinberg equilibrium. As the most
likely cause of this was genotyping error all sam-
ples thought to have a genotype containing an 4
allele were re-typed by Cfo1 restriction digestion—a
method based on Wenham et al. [44]. This method is
the standard APOE typing method used in the South
West Dementia Brain Bank but is not well suited to
high-throughput studies. Typing was performed by
examining the digestion products under UV light after
electrophoresis in a 3.5% agarose gel with ethidium
bromide.
Immunoperoxidase labelling of parafﬁn sections
The paraffin sections were incubated at 60◦C
overnight, then de-waxed in clearene (2 × 5 min)
and dehydrated in 100% alcohol (Fisher scien-
tific, 2 × 3 min). Endogenous peroxidase activity was
blocked by incubation in 3% H2O2 in 100% methanol
for 55 min before the sections were washed in running
water for 10 min. Antigen retrieval was performed
by boiling the sections in citric acid. The sections
were heated until boiling, then cooled for 5 min
before being heated again and boiled for 1 min. They
were then cooled for 20 min before being washed
in running water. Non-specific antibody binding was
blocked with 20% normal horse serum (Vector labs)
for 2 h. The sections were washed 2 × 3 min in PBS
before being incubated with the primary antibody
overnight (PSD-95, Sigma Aldrich P246; MAP2,
Sigma Aldrich M4403; drebrin, Abcam ab60932).
The following day the sections were washed in
PBS for 2 × 3 min, incubated with the universal sec-
ondary antibody (Vector labs) for 20 min, washed
again in PBS and incubated with Vecta Elite ABC
complex (Vector labs) for 20 min. After further
washes in PBS the sections were incubated with DAB
(Vector labs) for 10 min before being washed in run-
ning water for 10 min. They were then placed in 0.16
M copper sulphate for 4 min before a further wash in
running water for 5 min. They were counterstained
in Harris’s hematoxylin for 20 s and washed again in
running water for 15 min prior to dehydration, clear-
ing, and mounting.
The field fraction immunopositive for each antigen
was assessed by examining up to 20 random fields of
the cornu ammonis (CA1, 2, and 3 subfields) under a
20x objective. The software package Image Pro Plus
(Media Cybernetics, MD, USA) was used to select
the fields at random in the pre-defined area and for
image capture. For a small number of slides, the area
of included cornu ammonis was too small to accom-
modate 20 non-overlapping fields but at least 10 were
captured in all cases.
Double immunoﬂuorescent labelling of parafﬁn
sections
These sections were dewaxed in the same manner
as the immunohistochemistry slides. After de-waxing
the sections were washed in running water for 10 min
before citric acid antigen retrieval as above. The sec-
tions were blocked in 10% normal horse serum/0.1%
triton/PBS for 2.5 h (Vector labs, Sigma Aldrich)
before being incubated with the primary antibodies
diluted in 10% normal horse serum/0.1% triton/PBS
overnight (MAP2, Abcam ab5392, drebrin Abcam
ab11068 at 4◦C. After 3 × 3 min washes in PBS the
sections were incubated for 2 h with Alexa fluor-
conjugated secondary antibodies (Invitrogen) diluted
1:100 in 10% normal horse serum/0.1% triton/PBS.
Following this the sections were washed 3 × 3 min
in PBS prior to incubation in cupric sulphate (0.05
M ammonium acetate, 0.44 mM copper II sulphate,
pH 5.0) for 45 min. After quenching for 3 × 3 min in
dH2O the sections were placed in 3% Sudan black in
70% ethanol (Sigma Aldrich) for 6 min. The sections
were briefly dipped in 70% ethanol, then in dH2O,
mounted in vectashield (Vector labs) and sealed with
clear nail varnish. Representative images were taken
of the stratum radiatum of CA1.
Statistical analysis
All RT-PCR and protein assays were performed
blind to APOE genotype. Parametric statistical tests
were used where possible. If variables were not nor-
mally distributed, logarithmic transformation was
used to obtain a normal distribution, if possible.
For normally distributed variables linear regression
or ANOVA was used. For variables that were not
normally distributed, even after logarithmic transfor-
mation, Kruskal Wallis test and Dunn’s post hoc test
were used.
Pearson’s correlation was used to assess the effect
of postmortem delay. Due to the difficulties in recruit-
ment to this study, some tissue samples with a long
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postmortem delay (>72 h) were included. As protein
stability after 72 h had not been assessed experi-
mentally we made an a priori decision to conduct
sensitivity testing by re-running the analyses after
exclusion of samples with a postmortem delay >72 h
(see Supplementary Material). By using these two
methods, we could be more confident that any find-
ings were not an artefact of variation between groups
in postmortem delay. In addition, where postmortem
delay was shown to affect protein level, we used lin-
ear regression with postmortem delay included as
a variable. If the residuals were not normally dis-
tributed (and thus the assumptions of linear regression
violated), the variable was log transformed and the
distribution of the residuals re-checked. A threshold
for p values of 0.05 was used throughout.
RT-PCR results were analyzed by the 2−Ct
method [45]. This yields relative quantification rather
than absolute values for expression. Expression is
normalized to reference (calibrator) genes. This con-
trols for errors due to loading of differing amounts of
cDNA, operator handling, and differing intra-assay
variability. It is also suitable for studying low expres-
sion levels [45]. It is considered to be the best method
for comparing expression between groups and by
inclusion of appropriate calibrators can be used to
quantify expression restricted to a single type of cell
within a mixed population of cell types.
To maximize study power, the data were initially
analyzed as 4 versus non-4. To explore the findings
further, follow-up analysis used most of the APOE
genotype groups but was limited by low study power.
We made an a priori decision to exclude individuals
with an 42 genotype from analyses as this group
mixes the highest and lowest risk alleles. This is
standard practice in APOE research [46]. As each
individual variable is a crude proxy measure of pre-
or post-synaptic density and has measurement error,
a summary Z score was also used. This was calcu-
lated by normalizing each individual variable (x) to
the mean of that variable (), i.e., calculating (x-)/σ
where σ is the standard deviation, and then summing
the Z scores of individual variables to generate a pre-
and post-synaptic Z score [19, 47].
Power calculations based on previous published
work suggested a larger sample than we were able to
acquire from UK brain banks. For synaptic proteins,
taking synaptophysin as an example, the sample size
required to find a 5 OD/mg difference between the 2
groups with 80% power and an  of 0.05 would be 63
in each group. It was not possible to perform a formal
power calculation for the RT-PCR study [19].
Assay reliability
Although most of the assays generated repro-
ducible values, the SNAP-25 and drebrin assays
had lower reproducibility. The average measure
intra-class correlation co-efficients (ICCs) for synap-
tophysin, PSD-95, and septin 7 were 0.831, 0.846,
and 0.605 respectively, indicating excellent repro-
ducibility. The ICC for the drebrin assay was 0.174,
indicating low agreement between measurements on
different plates. The ICC for the SNAP-25 assay was
–0.103 for single measures and –0.389 for average
measures, indicating a low level of reproducibility.
RESULTS
As shown in Table 2, this was a relatively middle-
aged cohort with a mean age at death of 56.1 y
(SD 13.3 y). It included tissue from 56 individuals
aged <50 at death. APOE genotypes were avail-
able for all samples. Following our re-typing by the
Cfo1 method the genotypes were in Hardy-Weinberg
equilibrium (χ2 = 2.007,p = 0.571). There was no evi-
dence of a between-genotype group difference in age,
gender, postmortem delay, Braak stage, or cause of
death (see Table 1).
In total, tissue was received from 103 individuals.
After exclusion of those with an42 genotype, we had
95 samples of hippocampus and 100 of superior tem-
poral gyrus. For a small number of individuals, tissue
was not available for RNA extraction; in total 190
samples were available for RNA extraction. Braak
staging was performed by the modified method of
Braak et al. [48]. Because some of the sections of
temporal lobe from other brain banks did not include
the transentorhinal region and a few contained only
part of the full coronal extent of the hippocampus,
it is possible that some of the brains assigned a
Braak stage 0 were actually Braak stage I, and a few
assigned a Braak stage I were actually Braak stage
II. However, we could be confident that individuals
with AD were not included in our sample, as indi-
viduals with Braak stages I-II have a low probability
of AD [49].
Synaptic protein measurements
There was no evidence of a per-APOE genotype
difference in NSE, synaptophysin, or SNAP-25 in
either brain region (see Tables 2 & 3). The initial
ANOVA was strongly suggestive of a difference in
drebrin in the hippocampus between the genotype
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Table 2
Demographics and information on key variables for the brain bank cohort
33 34 44 32 22 Statistical group evidence for a
(n = 57) (n = 22) (n = 5) (n = 15) (n = 1) between difference
mean SD mean SD mean SD mean SD mean SD (χ2, F-test, Kruskal-Wallis or ANOVA)
Age at death (y) 56.5 13.6 57.8 12.0 40.2 13.0 61.5 11.9 48 Kruskal Wallis
χ2 = 8.746, p = 0.068
Gender χ2 = 1.835 p = 0.766
Female 12 4 0 2 0
Male 46 18 5 13 1
Cause of death χ2 = 32.340
CVD 26 15 3 3 1 p = 0.643
Cancer 10 3 0 6 0
Respiratory 7 1 0 1 0
Trauma 2 0 1 3 0
Postmortem delay (h) 51.2 25.6 51.8 17.7 62.0 15.2 47.3 26.6 95 Kruskal Wallis
χ2 = 4.752, p = 0.314
Braak stage Kruskal Wallis
0 14 4 6 χ2 = 0.003
I 9 4 1 p = 0.998
II 6 2 3
III 2 0 1
Neuropathology findings χ2 = 18.130
Normal 38 13 4 12 1 p = 0.796
Mild age-related changes 5 2 0 0 0
Small vessel disease 10 7 1 0 0
Other 4 0 0 3 0
STG NSE (ng/ l) 2.809 1.447 2.775 1.699 2.282 1.544 3.227 1.467 2.789 p = 0.875
Hippocampal NSE (ng/ l) 2.774 1.516 2.147 1.528 3.720 2.940 2.558 1.123 1.386 p = 0.180
Table 3
Summary of the study findings
Protein Brain Area ELISA Immunohistochemistry Gene expression (RT-PCR)
Synaptophysin Hippocampus ↔* N/A ↔
Superior Temporal Gyrus ↔ N/A Increased in 4 carriers
compared to 2 reference
genes
SNAP-25 Hippocampus ↔ N/A Decreased in 2 carriers
compared to 2 reference
genes
Superior Temporal Gyrus ↔ N/A ↔
Drebrin Hippocampus Small increase in 32 group ↔ ↔
Superior Temporal Gyrus ↔ N/A ↔
PSD-95 Hippocampus Trend towards an increase in
32 group
No strong evidence of a per
genotype difference
Increased in 4 carriers
compared to all 3 reference
genes
Superior Temporal Gyrus ↔ N/A ↔
Septin 7 Hippocampus ↔ N/A ↔
Superior Temporal Gyrus ↔ N/A ↔
*↔, no evidence of a per-genotype difference.
groups. Subsequent linear regression showed that
this was due to an increase in drebrin in the 32
group (= 0.632, 95% CI 0.285 to 0.943, p < 0.001).
This finding was unchanged when age-at-death and
postmortem delay were included as co-variates in a
sensitivity analysis (see Supplementary Tables 3 and
4). As shown in Supplementary Figure 1, it was also
not associated with Braak tangle stage. Although the
same trend was seen for PSD95 and septin 7 in the
hippocampus, the increase in these proteins was not
statistically significant. The summary post-synaptic Z
score supported the finding of a rise in post-synaptic
proteins in the hippocampus in the 32 group. As
the data were not normally distributed, Kruskal Wal-
lis test and Dunn’s post hoc test were used. The 32
group differed significantly from the 33 (p = 0.0007)
1130 L.I. Sinclair and S. Love / APOE Effects on Synaptic Proteins
and 34 (p = 0.0019) groups, and there was a trend
toward a difference from the 44 group (p = 0.0865).
Gene expression
Initial analysis of 4 versus non-4 revealed a
significant increase in 4 carriers in the expression
of DLG4 (the gene for PSD-95) compared to all 3
reference genes (see Figs. 2 and 6, Supplementary
Tables 23 and 25) in the hippocampus. This was not
seen in the analysis by individual genotypes, possi-
bly due to a reduction in power, although the result
for MAP2 was suggestive of a possible effect (see
Supplementary Table 3). We detected no other hip-
pocampal effects in 4 versus non-4 analysis.
SYP (synaptophysin) expression was increased
significantly relative to ENO2 and GAPDH in the
superior temporal gyrus in 4 carriers (see Fig. 7),
and non-significantly relative to MAP2 (see Supple-
mentary Tables 24 and 26). Analysis by individual
genotype (see Supplementary Table 4) did not reveal
strong evidence of a per-genotype difference in gene
expression.
Immunohistochemistry
Antibodies to MAP2, drebrin, and PSD-95 labelled
cornu ammonis dendrites, particularly those in the
stratum radiatum (Fig. 4), and neuronal perikarya.
Whereas the immunolabeling of dendrites for MAP2
Fig. 1. Post-synaptic protein levels in the hippocampus. All protein concentrations were adjusted for total protein and neuronal content. As
shown the evidence was strongest for an increase in drebrin in the 32 group, although the same pattern was seen for all three post-synaptic
proteins. The summary/Z score provided further statistical evidence of a between-group difference.
Fig. 2. Gene expression of DLG4 (gene for PSD95) in the hippocampus. As shown there was evidence of a between-group difference with
respect to all three reference genes.
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Fig. 3. Results from the immunohistochemical (IHC) field fraction
study. Areas under investigation were CA1, 2, and 3.
and drebrin appeared continuous, the pattern of
labelling of PSD-95 was punctate or granular. As
shown in Fig. 5, there was overlap in the distribution
of MAP2 and drebrin. As shown in Supplementary
Table 27 and Fig. 3, there was no clear evidence of
Fig. 4. Representative images of staining for (A) MAP2, (B)
Drebrin, and (C) PSD-95 in the stratum radiatum of CA1.
a difference in the field fraction immunopositive for
either drebrin or MAP2 in the hippocampus. There
was a trend toward a lower PSD-95 field fraction in
the 33 group (p = 0.066). Unfortunately, the lim-
ited availability of cases with a sufficient amount
of residual hippocampus in the paraffin blocks for
immunohistochemical quantification of these anti-
gens reduced the power of this part of the study.
DISCUSSION
In this relatively large series of normal brains from
adults aged between 18 and 75 y, we have found evi-
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Fig. 5. Representative double labelled immunofluorescence staining of (A) MAP2, (B) drebrin, and (C) combined in the stratum radiatum
of CA1. As can be seen, the staining for drebrin is very punctate but does have some overlap with MAP.
Fig. 6. Results from the gene expression study in the hippocampus with GAPDH used as the reference gene. As shown in (E), expression
of DLG4 (the gene for PSD-95) appeared to be increased in 4 carriers.
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Fig. 7. Results from the gene expression study in the superior temporal gyrus (STG) with GAPDH used as the reference gene. As can be
seen in (A) and (D) there was a suggestion that expression of SYP and SEPT7 was increased in 4 carriers but there was no evidence of any
other differences between the APOE genotype groups.
dence of an increase in post-synaptic proteins in the
hippocampus of those with an APOE 32 genotype.
The evidence was strongest for drebrin, but as shown
in Fig. 1, the same direction of effect was seen
for all three post-synaptic proteins measured. The
post-synaptic Z score for the hippocampus provided
further evidence in support of an increase in post-
synaptic proteins in the 32 genotype group. Contrary
to our hypothesis, we did not find a difference in
synaptic protein levels (as measured by ELISA) in
those with an 4APOE allele compared to those with-
out, and there was no relationship between levels of
pre-synaptic proteins and APOE genotype in either
the hippocampus or the superior temporal gyrus. The
results are summarized in Table 3.
Some animal studies have suggested that the con-
centration of synaptophysin in the hippocampus starts
to decrease very early in the development of AD. In
one study, mice as young as 4 months with the human
APOE4 gene exhibited a reduction in synaptophysin
[24], although in another study no difference could be
seen before 12 months (equivalent of human old age)
[26]. Human studies have provided some evidence
that synaptophysin may increase at an early stage
in AD before decreasing as the dementia becomes
more severe [23]. The lack of effect of the 4 allele
in the present study may be because our cohort was
too young or may be due to a genuine null effect.
Although drebrin has been shown to be reduced
in AD, it has not previously been studied in relation
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to APOE genotype in the absence of AD [22, 34].
PSD-95 was reduced in older non-demented controls
in one study, but the relationship of this to AD is
unclear [19]. Two recent studies suggested that PSD-
95 declines relatively late in the AD disease process
and that it is redistributed from apical dendrites to
the nerve cell body as A and tau pathology worsen
[50, 51]. If the reduction is indeed later in the dis-
ease process, then this may explain our null finding.
Previous research has not established a clear rela-
tionship between SNAP-25, APOE, and AD. Again
contrary to our hypothesis, we did not find reduced
transcript levels of synaptic proteins in 4 carriers.
Instead there was increased DLG4 gene expression in
the hippocampi of 4 carriers in relation to all three
reference genes. In the superior temporal gyrus, there
was evidence of increased expression of the genes
for three synaptic proteins in 4 carriers. This evi-
dence was most robust for the SYP gene although
not in relation to MAP2. The dissociation between
synaptic protein and transcript levels has a number of
possible explanations. Protein tends to be more sta-
ble postmortem than mRNA, although this too varies
depending on the protein. In the present study, we
measured proteins that we had shown to be relatively
stable under postmortem conditions. Fleige et al. [52]
showed that RNA integrity (as indicated by the RIN
value) influenced the Ct of RT-PCR but that this effect
was reduced (although not eradicated) by normaliza-
tion to a reference gene. Fleige et al. also commented
that RT-PCR amplicons of <250 bp generate results
that are to some extent independent of the quality
of the initial RNA [53] and they recommended using
amplicons no longer than 200 bp to obtain reliable RT-
PCR results. An independent group replicated these
findings [54]. The amplicons used in this study were
all ≤111 bp and mostly <100 bp. Several previous
authors have found weak or inconsistent correlation
between mRNA and protein levels [55–58].
Carriage of an 2 allele is known to reduce the risk
of an individual’s developing AD, possibly by up to
two-thirds [7–9]. Some, but not all, studies have sug-
gested that this protection may lessen in extreme old
age as other factors, such as vascular disease, become
more important than neurofibrillary tangles and amy-
loid plaques in the development of dementia. There
is some evidence that below the age of 80, 2 carriers
have less AD neuropathology but that after this age
they have as much as those with 4 alleles [10, 11].
In the (relatively small) study by Berlau et al., 2
carriers had significantly more AD neuropathology
than the reference 33 group but a reduced likeli-
hood of dementia (OR of 0.3) [10]. In a follow-up
study, non-demented 2 carriers had smaller, denser
amyloid plaques than 33 homozygotes or 4 carriers
[59]. The authors wondered whether the E2 protein
sequestered A into plaques more effectively than
other isoforms of apolipoprotein E, reducing the level
of toxic oligomers. They also speculated as to whether
some other unknown compensatory mechanism is
present in those with an 2 allele [10, 59]. Recent
research by Chung et al. which showed that the E2
isoform of ApoE increased synaptic phagocytosis by
astrocytes (with possible evidence of fewer senescent
synapses) may explain some of the findings [60].
The E2 protein has been shown in animals to
increase early dendrite development, to bind Amore
strongly and to be more resistant than the other iso-
forms to degradation [61–63]. Several studies have
demonstrated that E2 promotes dendrite formation
or regeneration. In a small study in mice, posses-
sion of 2 protected against dendritic spine loss in
the hippocampus of mice transgenic for APP [64].
An interesting transgenic mouse experiment (human
APOE gene, mouse promoter), in which 2 was,
unfortunately, studied only in combination with 4,
found that 2 reversed synaptic deficits detected by
electrophysiology in brain slices but did not fully
reverse the reduction in dendritic arbors at 7 months
of age [65]. A further in vitro study, in which wild
type mouse neurons were co-cultured with trans-
genic mice astrocytes, found that compared to E3
and E4 astrocytes, E2 astrocytes accelerated the
development of dendritic spines [66]. As mature den-
dritic spines contain NMDA receptors and PSD-95
is an NMDA scaffold protein, this may explain the
observed changes in both drebrin and PSD-95 [66].
In contrast, a study of neurite outgrowth in cultured
mouse olfactory epithelial cells found that recombi-
nant E2 promoted neurite outgrowth less than E3 but
more than E4 [67]. A previous study by our group
found a 17% increase in PSD-95 in the superior tem-
poral cortex of older adults without dementia who had
at least one 2 allele [19]. A small transgenic mouse
study, which used western blots to measure PSD-95
and drebrin, also suggested (but did not prove) that
drebrin may be increased in 2 carriers [68].
Most studies in the field of AD have looked at
those who either have pathological abnormalities or
who are elderly and at high risk. We set out to study
the effects of APOE on synaptic proteins in early to
mid-adult life. Contrary to our hypothesis that 4 car-
riers would have lower levels of synaptic proteins and
lower expression of the relevant genes we did not find
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any differences in this group at elevated genetic risk of
AD. Instead we found possibly protective differences
in carriers of the 2 allele, which reduces the risk
of AD.
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